Acute Rejection
Acute Rejection - Related Videos
08:42
A Standardized Murine Model with a Three-Person Workflow for Studying Acute Cellular and Antibody-Mediated Rejection in Xenotransplantation
0 Views •
2026
This study establishes two standardized murine xenotransplantation models to specifically replicate acute cellular rejection and acute antibody-mediated rejection. These models serve as a reliable platform for investigating mechanisms of xenograft immune rejection, evaluating immunosuppressive strategies, and advancing preclinical xenotransplantation research.
16:26
Regulatory T cells: Therapeutic Potential for Treating Transplant Rejection and Type I Diabetes
0 Views •
Cited by 2 •
2007
07:05
Mouse Model of Alloimmune-induced Vascular Rejection and Transplant Arteriosclerosis
0 Views •
Cited by 7 •
2015
We describe a protocol for aortic interposition grafting in mice. The goal of the protocol is to provide a model with which to study pathological processes and therapeutic strategies relevant to alloimmune reactions in arteries and the resultant arterial changes that contribute to organ transplant failure.
17:13
Non-invasive Imaging of Acute Allograft Rejection after Rat Renal Transplantation Using 18F-FDG PET
0 Views •
Cited by 12 •
2013
We herein present a rat renal transplantation model to non-invasively assess acute allograft rejection using positron emission tomography with 18F-fluorodeoxyglucose.
FAQs
Recipient T cells are central to acute rejection because they can recognize donor human leukocyte antigens, or HLA, as foreign. That recognition activates a cellular immune response, producing inflammation within the graft. The resulting injury can reduce organ performance, linking donor-recipient differences with clinically significant transplant dysfunction.
Antibody-mediated injury provides a second route of graft damage. In some episodes, antibodies target structures associated with the donor graft and injure its blood vessels. Vascular injury can compromise the graft’s environment and function, so evaluation must consider more than T-cell-driven cellular inflammation when assessing suspected rejection.
Acute rejection typically emerges days to months after transplantation rather than at one fixed interval. This timing makes continued surveillance important after the procedure, because graft problems may develop during a prolonged post-transplant window. Monitoring during this period helps clinicians recognize changes in organ function and investigate them promptly.
Assessment combines several types of evidence rather than relying on one finding. Clinicians follow organ function and laboratory markers, use imaging findings, and evaluate biopsy results. This integrated approach helps distinguish acute rejection from infection or drug toxicity, which may also be associated with concerning changes but require different clinical interpretation.
Clinicians treat acute rejection with immunosuppressive therapy to reduce the immune attack on the graft. Prompt treatment can restore graft function, but evaluation must first help separate rejection from infection or drug toxicity. Rapid assessment therefore supports timely therapy while reducing the risk of treating the wrong cause of dysfunction.
Research is seeking more precise biomarkers that could identify acute rejection more accurately during transplant evaluation. Another goal is tolerance-based treatment, designed to reduce rejection without excessive immune suppression. Together, these approaches aim to make care more selective while improving the ability to preserve graft function after transplantation.